Fred Hutch's Lynch, Sarah Cannon's Burris discuss NIH funding cuts in a top episode from TCL's "The Directors" series. (@fredhutch.org, @scri.com) https://cancerletter.com/podcastc/20250516_1/

A 2025 top story: As fire encroached, City of Hope prepared to evacuate its Duarte campus. (@cityofhope.bsky.social) https://cancerletter.com/the-cancer-letter/20250110_2/

The dissolution of NCI's BSA was among 2025's top stories—a board established nearly 3 decades ago to focus on extramural research. https://cancerletter.com/news-analysis/20250502_4/

TCL readers were moved this year by a farewell group photo from staff members of NCI’s dissolved communications team. https://cancerletter.com/cancer-policy/20250523_8a/

A 2025 podcast TCL listeners loved most: Congress rejects Trump's 40% NIH cuts. House bill adds $48M to NCI, $99M to NIH. https://cancerletter.com/podcastc/20250910-nih-funding/

The inaugural episode of "The Directors" featured VCU's Winn and City of Hope's Carpten—and was The Cancer Letter's top podcast episode of 2025. (@cityofhope.bsky.social, @vcumassey.bsky.social) https://cancerletter.com/podcastc/20250214_1/

In The Cancer Letter's top story of 2025, a post by an NCI employee triggered accusation of “undermining the Trump administration.” https://cancerletter.com/cancer-policy/20250530_5a/

Dana-Farber to pay $15M to U.S. government in research fraud settlement https://cancerletter.com/cancer-policy/20251219_7d/

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds https://cancerletter.com/clinical-roundup/20251219_9d/

“We need to be also accountable and responsible for how we communicate the good news and the bad to the American public,” said Robert Winn (@aacicancer.bsky.social, @vcumassey.bsky.social) https://cancerletter.com/podcastc/20251219_1/

Richard Jones, Sidney Kimmel Comprehensive Cancer Center: "The NCI also must be delighted by the efficiencies in the new review process, including the projected cost savings of hundreds of thousands of dollars." https://cancerletter.com/guest-editorial/20251219_2/

Reimagine Care, Tampa General collaborate to improve cancer care delivery https://cancerletter.com/in-brief/20251219_8d/

Since 2019, we have been mining The Cancer Letter’s analytics to catch a glimpse of what’s capturing you and your colleagues’ attention each year. In 2025, it’s no question that health care policy has taken center stage. https://cancerletter.com/editorial/20251219_5/

ACS cancer disparities report: Major differences in mortality burden by urbanicity, congressional district, socioeconomic status, and race/ethnicity (@acscan.bsky.social) https://cancerletter.com/clinical-roundup/20251219_9c/

Winn considers this renewed attention to communicating cancer progress a “silver lining” to the past year of instability. (@vcumassey.bsky.social, @aacicancer.bsky.social) https://cancerletter.com/podcastc/20251219_1/

EC approval of Minjuvi in relapsed or refractory follicular lymphoma https://cancerletter.com/drugs-and-targets/20251219_10d/

“We have known about the relationship between alcohol and cancer for a long time.” - Julie Gralow, ASCO. (@ascocancer.bsky.social) https://cancerletter.com/the-cancer-letter/20251219_3/

Ohio State to be awarded funding to optimize sarcoma treatment https://cancerletter.com/in-brief/20251219_8c/

ASCO publishes guideline on treating pregnant women with blood cancers (@ascocancer.bsky.social) https://cancerletter.com/clinical-roundup/20251219_9b/

Northwell, START unveil $5.7M early-phase clinical trial center (@northwellhealth.bsky.social) cancerletter.com/in-brief/202...

AACI President Dr. Joann B. Sweasy, director of Fred & Pamela Buffett Cancer Center & Immediate Past President Dr. Robert A. Winn, director of @vcumassey.bsky.social, recently appeared together on @cancerletter.com The Directors podcast. Watch it here: youtu.be/K1-sEsU7_kA #DefendingCancerResearch

MUSC's Ogretmen: “We’re not only targeting cancer cells, we’re dismantling their internal infrastructure and exploiting a fundamental weakness in how those cells manage energy and stress.” https://cancerletter.com/sponsored-article/20251219_6/

FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results https://cancerletter.com/drugs-and-targets/20251219_10c/

Brown cancer center director addresses campus shooting https://cancerletter.com/cancer-policy/20251219_7c/

"Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity," writes Richard J. Jones, MD for Sidney Kimmel Comprehensive Cancer Center https://cancerletter.com/guest-editorial/20251219_2/

New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate. https://cancerletter.com/the-cancer-letter/20251219_3/

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma https://cancerletter.com/drugs-and-targets/20251219_10b/

Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, MD Anderson-led study finds (@mdanderson.bsky.social) https://cancerletter.com/clinical-roundup/20251219_9a/

“Cancer research is apolitical,” said Joann Sweasy, director of the Fred & Pamela Buffett Cancer Center and president of the Association of American Cancer Institutes. (@unmc.bsky.social, @aacicancer.bsky.social) https://cancerletter.com/podcastc/20251219_1/

Harvey Risch appointed chair of President’s Cancer Panel https://cancerletter.com/cancer-policy/20251219_7b/

2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission. https://cancerletter.com/editorial/20251219_5/

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer https://cancerletter.com/drugs-and-targets/20251219_10a/

Should I have a drink tonight? In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in https://cancerletter.com/the-cancer-letter/20251219_3/

Mitochondrial-targeting drug attacks cancer cells from within - guest editorial by Hayley Kamin, MUSC Hollings Cancer Center (@muschollings.bsky.social) https://cancerletter.com/sponsored-article/20251219_6/

Guest editorial by Sidney Kimmel Comprehensive Cancer Center's Richard J. Jones: With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025 https://cancerletter.com/guest-editorial/20251219_2/

MSK’s Deb Schrag elected president-elect of ASCO (@ascocancer.bsky.social) https://cancerletter.com/in-brief/20251219_8a/

Angelo de Claro named acting director of FDA Oncology Center of Excellence https://cancerletter.com/cancer-policy/20251219_7a/

The Directors: Joann Sweasy and Robert Winn reflect on lessons learned during a tough year Current and former @aacicancer.bsky.social presidents agree: strategic communication is key to safeguarding the future of cancer research https://cancerletter.com/podcastc/20251219_1/

The Cancer Letter’s most-read stories of 2025: As MAHA-led policies took hold, oncology navigated through uncertainty and turmoil https://cancerletter.com/editorial/20251219_5/

Eflornithine + lomustine extend OS for patients with recurrent IDH mutant, grade 3 astrocytoma, phase III data show https://cancerletter.com/clinical-roundup/20251212_6d/

Public health advocates and lawmakers expressed outrage over the withdrawal, with one congressional critic calling it “reckless and dangerous.” https://cancerletter.com/regulatory-news/20251212_2/

Robin Toft named CEO of Curebound https://cancerletter.com/in-brief/20251212_5d/

Off-the-shelf immunotherapy produces deep and durable responses in extramedulary MM, @mayoclinic.org researchers find https://cancerletter.com/clinical-roundup/20251212_6c/

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it? https://cancerletter.com/podcastc/20251217-talc/

White House directs HHS and CDC to align childhood vaccine recommendations with “best practices from peer, developed countries” https://cancerletter.com/cancer-policy/20251212_4d/

John C Byrd, MD: "You can always be aligned better and have teams working better, and when you stop working to get better, then it’s time to stop working." https://cancerletter.com/conversation-with-the-cancer-letter/20251212_1/

FDA approves robotic-assisted surgery system for urologic surgical procedures https://cancerletter.com/drugs-and-targets/20251212_7d/

The two guidances are the first from a major oncology group to provide detailed advice on how to use AI in a way that maximizes benefit and mitigates risk. https://cancerletter.com/regulatory-news/20251212_3/

AACR Project GENIE receives 2025 Amazon Web Services Imagine Grant for nonprofits (@theaacr.bsky.social) https://cancerletter.com/in-brief/20251212_5c/

ACS updates guidelines for cervical cancer screening (@americancancersoc.bsky.social) https://cancerletter.com/clinical-roundup/20251212_6b/